Drug Profile
FF 10501
Alternative Names: FF 10501 01; FF-10501; IMPDH inhibitor FF-10501Latest Information Update: 01 Dec 2022
Price :
$50
*
At a glance
- Originator FUJIFILM Holdings Corporation
- Developer FUJIFILM Holdings Corporation; Strategia Therapeutics
- Class Antineoplastics
- Mechanism of Action Inosine monophosphate dehydrogenase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Acute myeloid leukaemia; Chronic myelomonocytic leukaemia
- No development reported Myelodysplastic syndromes
Most Recent Events
- 01 Dec 2022 No development reported - Phase-II for Myelodysplastic syndromes (Second-line therapy or greater) in USA (PO)
- 23 Oct 2019 Fujifilm Pharmaceuticals completes a phase I/II trial in Acute myeloid leukaemia, Chronic myelomonocytic leukaemia and Myelodysplastic syndromes (Second line therapy or greater) in USA (NCT02193958)
- 28 May 2019 No recent reports of development identified for phase-I development in Myelodysplastic-syndromes in Japan (PO, Tablet)